ADHD Medication Shortage UK: Why It Happens and What You Can Do

A plain-English guide for patients and parents, including where to find a pharmacy with stock near you.

6- minute read | Written by: Irene Akladious, Integrated Care Pharmacist

You have done everything right. The GP appointment took weeks. The prescription is finally in hand. And then you arrive at the pharmacy and they do not have it.

Whether you are collecting for yourself or for your child, that moment is genuinely exhausting. Not just inconvenient. Exhausting in a way that is hard to explain to people who have not been through it.

If this has happened to you, you are not alone and you have not done anything wrong. The ADHD medication shortage in the UK has been ongoing since late 2023 and continues to affect patients across the country. Here is a clear, honest explanation of why it keeps happening and what you can actually do about it.

Is there really an ADHD medication shortage in the UK?

Yes. The ADHD medication shortage in the UK is real and has been confirmed by NHS guidance, clinical bodies and pharmacists across the country. It began in September 2023 and, as of 2026, intermittent disruptions continue- particularly for some methylphenidate preparations.

The official explanation, stated consistently in NHS-facing updates, comes down to two things happening at once:

1. A sharp and sustained rise in global demand for ADHD medication

2. Manufacturing problems that have slowed production across multiple suppliers

These two forces have collided and are reinforcing each other. That is why the situation has been so persistent. Just when one product seems to stabilise, another slips into shortage.

Why has demand for ADHD medication risen so sharply?

For a long time, ADHD was significantly underdiagnosed, particularly in adults and particularly in women and girls. Growing clinical awareness and a better understanding of how ADHD presents across different people means that thousands of adults who would previously have gone unrecognised are now receiving diagnoses.

That is genuinely good news. But the supply chain was not built for this pace of change. Manufacturers had not scaled up. The system was designed for a world where ADHD was considered a childhood condition affecting a small number of children, not the much broader reality we now understand

More people finally getting the right diagnosis is a good thing. The supply chain just was not ready for it.

Who has been most affected by underdiagnosis?

The underdiagnosis picture is not uniform. Certain groups have historically faced greater barriers to receiving a diagnosis, and the evidence points clearly to two overlapping inequalities: gender and ethnicity.

On ethnicity, UK screening data suggests that Black people are actually more likely to screen positive for ADHD than White British people (13% versus 10.2%), and yet research consistently shows that people from Black and other minoritised communities are far less likely to receive a formal diagnosis. International studies have found diagnosis rates among racially and ethnically minoritised young people can be less than half the rates of their White counterparts, even when presenting with identical symptoms. The NHS England independent ADHD Taskforce has explicitly identified minority groups as facing significant inequalities in access to care.

The reasons behind this gap are structural as well as cultural. They include:

•  Mental health stigma in some communities, where ADHD symptoms may be attributed to behaviour, parenting or character rather than a neurodevelopmental condition

•  Clinician bias, conscious and unconscious, which can lead to ADHD symptoms being interpreted differently depending on a child's or adult's background

•  Language barriers, which can affect both the person seeking a diagnosis and the reliability of symptom reporting

• Reduced access to mental health services more broadly, including longer waits and less continuity of care in some areas

A note on the UK evidence: much of the strongest diagnostic disparity data comes from the United States. UK-specific research is growing but less comprehensive. The NHS consensus statement on ADHD (2021) acknowledged that more UK research is specifically needed on ethnic and racial biases in diagnosis and treatment. The direction of the evidence is consistent and concerning. The scale of the gap in a UK context requires further investigation.

What this means in practice is that many people from Black and ethnic minority communities may be further back in the diagnosis queue, and therefore further back in the prescribing queue. As demand continues to rise and the shortage persists, those who waited longest for diagnosis may also find themselves navigating a depleted supply at the very moment they finally have a prescription.

Why cannot manufacturers simply produce more ADHD medication?

ADHD stimulant medications are controlled medicines under UK law. That means the raw ingredients and the quantities that can be manufactured are subject to tight regulatory controls, both domestically and internationally.

Expanding production is not like turning up the dial on the thermostat. It requires regulatory approval, new licensing and in some cases sourcing raw materials that are themselves internationally restricted. Even manufacturers who want to produce more face real legal and logistical limits on how quickly they can do so.

This is why the shortage has not resolved quickly. It is not for lack of trying. It is because the system governing the production of controlled medicines moves slowly by design.

Why does switching ADHD medication just move the problem elsewhere?

When one product runs short, GPs and pharmacists often suggest switching to an alternative, which is the right clinical instinct. But it has an unintended consequence: the demand pressure does not disappear; it moves. The previously available product then faces a new surge and a secondary shortage follows it there too.

NHS guidance has noted this ripple effect directly. It is one of the main reasons multiple medications and multiple dose strengths have been affected throughout the shortage period, not just one product from one manufacturer.

The ADHD medication shortage is not one brand's problem. It is a systemic strain across the whole market.

Why does one pharmacy have ADHD medication in stock and another does not?

This is one of the most common questions people searching for ADHD medication ask, and the answer surprises a lot of people. Two pharmacies on the same street can have completely different stock, and neither of them is doing anything wrong.

UK pharmacies generally source their medicines through wholesale distributors rather than directly from manufacturers. The major wholesalers supplying the sector include AAH Pharmaceuticals, Alliance Healthcare, Mawdsley-Brooks and Phoenix Healthcare. Which wholesaler a particular pharmacy uses determines what arrives on its shelves. NHS pharmacy guidance has confirmed that availability varies precisely because of this.

It is worth asking more than one pharmacy before giving up. The stock picture can genuinely differ by just a few streets.

ADHD medication shortage and children: what parents need to know

If your child's medication is prescribed through CAMHS (Child and Adolescent Mental Health Services) rather than your GP, the guidance their team follows during a shortage may be different from general NHS advice.

CAMHS services vary by region and some have their own prescribing protocols and switching guidance that differs from what a GP or adult service might recommend. During a shortage, this means:

•The alternative a GP might suggest may not be what your CAMHS team would prescribe

•Your CAMHS team may have access to different information about local supply

•Any switch or change in dose should ideally go through the service that originally prescribed it

If your child's medication is affected and they are under CAMHS, contact your CAMHS team directly rather than asking your GP to make changes independently. Keeping that prescribing relationship joined up matters, especially during a shortage.

Is the ADHD medication shortage only happening in the UK?

No. The ADHD medication shortage is a global problem. The United States, Australia and several other countries have experienced the same disruption: rising prescribing rates running ahead of what manufacturers could supply, compounded by the regulatory complexity of producing controlled medicines.

The root causes are consistent across countries. The UK shortage is part of a worldwide supply and demand imbalance that multiple health systems are dealing with simultaneously.

Which manufacturers are involved in the UK ADHD medication shortage?

The shortage is not one manufacturer's failure. Multiple companies have been caught in the disruption cycle. Those most associated with ADHD medication supply in the UK include:

• Takeda, manufacturers of several ADHD medications sold in the UK

• Janssen-Cilag, a Johnson & Johnson subsidiary, associated with a widely-used methylphenidate product

• Various generic manufacturers who supply the broader methylphenidate and other ADHD medication market and who have also been part of the shortage cycle

Where to find detailed clinical information about ADHD medication, including medicine names

MedPals cannot name specific prescription medicines in our content. That is a legal requirement under UK advertising rules. But we know that is not always what you need when you are trying to understand your options.

The resources below are published by clinical and patient information services. They do name specific medications, dose forms and switching guidance, because that is exactly what they are designed for. We are pointing you towards them because they are trustworthy and useful, not because we are endorsing any particular medicine.

Choice and Medication: Clinical Resources

Choice and Medication is a well-regarded UK clinical information service used by NHS trusts, mental health services and patient groups. Their ADHD resources are written for patients and carers as well as clinicians and are regularly updated.

•       ADHD Medications: UK Handy Chart: a side-by-side overview of ADHD medications available in the UK, including formulations and key differences. A useful starting point if you are trying to understand what alternatives might exist

•       Switching from Methylphenidate: Factsheet: clear guidance on what switching away from methylphenidate-based medicines involves clinically, including what to discuss with your prescriber

•       ADHD Medication Forms Explained: explains the different formulations of ADHD medication (immediate release, modified release and so on) and what they mean practically. Useful when a shortage means considering a different form of the same medicine

These resources are produced by Choice and Medication, an independent clinical information service. Always discuss any changes to your or your child's medication with your prescriber or pharmacist before acting on clinical information.

What can you do if you cannot get your ADHD medication?

•Ring ahead before making the trip. Ask the pharmacy whether your specific medication and dose strength is in stock. It saves a wasted journey.

• Try more than one pharmacy. Stock genuinely varies by wholesaler, so a pharmacy a few streets away might have what your usual chemist does not.

• Keep your prescriber in the loop. If you are repeatedly unable to fill a prescription, they need to know. There may be clinical alternatives worth exploring together.

• If your child is under CAMHS, contact that team directly. Do not rely on a GP making changes independently if CAMHS are the lead prescriber.

•Order early. Request your next prescription when you have around 14 days of medication remaining to allow the pharmacy time to source stock.

•Report shortages when you find them. Every report adds to the picture of where supply gaps are falling hardest and helps others in your area plan ahead.

HOW MEDPALS CAN HELP

Medpals is a practical tool for exactly this kind of situation.

Medpals' FindMyMeds lets you search for pharmacies near you that have your medication in stock before you leave the house. No calls, no guesswork and no wasted trips.

Medpals' ShareAShortage lets you report a shortage in seconds when you cannot find what you need. It helps to build a clearer picture of where supply is failing so that others in your community can plan ahead.

Medpals is free to use. No account needed. No personal data stored.

Try Medpals today. Because getting this right first time really matters.

A final word

If you have been navigating this, possibly while also managing a household, a job and a child who needs their medication, please know that the difficulty you are experiencing is real and it is not your fault.

The system has genuinely struggled to keep pace with demand. You are doing something hard. We hope Medpals makes even a small part of it a little easier.

This blog is for general information only and does not constitute medical advice. Please speak to your GP, pharmacist or prescribing team before making any changes to medication. The Choice and Medication resources linked above are produced by an independent clinical information service. Medpals is pointing you towards them as useful references, not endorsing any specific medicine. Medpals works alongside, not instead of, your NHS healthcare team.